In conclusion, it can be stated that the body of evidence reported so far concerning the impact of ABC transporters on drug resistance or tumor progression in ES needs to be expanded in order to clarify whether these candidate biomarkers may be considered to modulate or innovate treatment strategies for this tumor. The gene discussed is ABCG2; the disease is neoplasm.